Air Quality Monitoring System Market worth $6.0 billion by 2025

The report “Air Quality Monitoring System Market by Product (Indoor, Outdoor, Portable, Wearable), Sampling (Continuous, Manual, Intermittent), Pollutant (NO, VOC, Particulate Matter, Biological), End-user (Government, Petrochemical, Pharma)- Global Forecast to 2025" The global air quality monitoring system market (AQMS) is expected to reach USD 6.0 billion by 2025 from USD 4.3 billion in 2019, at a CAGR of 5.6%. 

The major factors driving the growth of the air quality monitoring system market include the supportive government regulations for effective air pollution monitoring and control, ongoing initiatives towards the development of environment-friendly industries, increasing public-private funding for effective air pollution monitoring, rising levels of air pollution, and increasing public awareness related to the environmental and healthcare implications of air pollution.

Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=183784537

The indoor air quality monitors segment accounted for the largest share of the market in 2019

Based on the product, the air quality monitoring system market is segmented into indoor monitors (comprising fixed and portable monitors), outdoor monitors (comprising fixed, portable, dust, and particulate monitors as well as AQM stations), and wearable monitors. The indoor monitors segment dominated the AQMS market in 2019. The large share of this segment is attributed to the increasing adoption of smart home and green-building technologies and growing consumer preference for pollution-free indoor environments.

Government agencies and academic institutes held the largest share of the AQMS market in 2019

Based on end-user, the air quality monitoring system market is segmented into government agencies and academic institutes, commercial and residential users, petrochemical industry, power generation plants, pharmaceutical industry, smart city authority, and other end users. The government agencies and academic institutes segment accounted for the largest share in 2018. The large share of this segment can be attributed to the presence of stringent environmental regulations, rising government investments for effective AQM, and increased installation of AQM stations worldwide.

North America to dominate the AQMS market during the forecast period

Geographically, the AQMS market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America held the largest share of the market in 2019. Factors such as easy accessibility and fast adoption of advanced technologies among key stakeholders and the presence of stringent government regulations for effective pollution monitoring and control are contributing to the large share of the North American region.

Request Sample Pages@ 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=183784537

The major players operating in the AQMS market include Thermo Fisher Scientific (US), Emerson Electric (US), General Electric (US), Siemens AG (Germany), Teledyne Technologies (US), PerkinElmer, Inc. (US), Agilent Technologies, Inc. (US), Spectris plc (UK), 3M Company (US), Honeywell International Inc (US), HORIBA, Ltd. (Japan), Merck KGaA (Germany), TSI Incorporated (US), Tisch Environmental (US), and Testo (Germany), among others.

Slep Apnea Devices Industry to Experience Global Growth in Revenue Generation

The global sleep apnea devices market is expected to reach USD 7.5 billion by 2024 from USD 4.5 billion in 2019 at a CAGR of 10.7%.

The major factors driving the growth of the sleep apnea devices market are primarily a large pool of undiagnosed sleep apnea patients, growing awareness about the ill effects of untreated sleep apnea, growing usage of oral appliances, technological advancements in sleep apnea devices, considerable venture capital funding, and an increasing number of companies venturing into sleep apnea and oral appliances markets.

The study involved four major activities in estimating the current market size for sleep apnea devices. Exhaustive secondary research was done to collect information on the market and its different sub-segments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter market breakdown and data triangulation was used to estimate the market size of segments and sub-segments

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=719

Report Objectives

# To define, describe, and measure the global market by type, end user, and region

# To provide detailed information about major factors influencing market growth (such as drivers, restraints, growth opportunities, and challenges)

# To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the global market

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

# To forecast the size of the market in North America, Europe, Asia Pacific (APAC), and the Rest of the world (RoW)

# To strategically analyze the market structure and profile key players and their core competencies3 in the global market

# To track and analyze competitive developments such as service launches, expansions, acquisitions, partnerships & collaborations; in the market.

Market Dynamics:

Driver: Large pool of undiagnosed sleep apnea patients

Although highly prevalent in the elderly, sleep apnea affects people of all ages and is one of the most common sleep disorders across the globe. The health impact of sleep apnea is quite substantial but under-recognized.

Worldwide data suggests that sleep apnea impacts more than 936 million people worldwide, which is nearly 10 times greater than previous estimates (Source: ResMed). In the US alone, around 22 million Americans suffer from obstructive sleep apnea (OSA); of which, 80% of moderate and severe OSA cases are undiagnosed [Source: American Sleep Apnea Association (ASAA)]. In the UK, OSA affects an estimated 1.5 million adults; up to 85% of these cases are undiagnosed or untreated. In countries with huge population bases, such as India and China, the diagnosis rate of OSA is <1% (Source: Press Trust of India, 2017 and China.org.cn).

Key Questions Addressed by the Report:

# Which type segment will dominate the sleep apnea devices market in the future?

# Emerging countries have immense opportunities for the growth and adoption of sleep apnea devices, therefore will this scenario continue in the next five years?

# Where will all the advancements in technology offered by various companies take the industry in the mid to long term?

# What are the upcoming alternative therapies and devices related to the same in the sleep apnea devices market?

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=719

Restraint: High cost of CPAP machines

In most developed countries, the cost of a CPAP device is either reimbursed or provided by medical insurance companies. The main reason for non-adherence is non-acceptance on the part of the patient, mainly due to the mask causing discomfort or claustrophobia. However, conditions are different in most developing countries, where insurance access is minimal and insurance companies usually do not cover the cost of a CPAP device.

Opportunity: Increasing focus on telemedicine and mHealth (mobile health)

Several studies have reported that a main predictive factor for long-term CPAP compliance is patient adherence in the first few weeks of treatment. To improve compliance, support and follow-up during this period must be prompt. Telemedicine offers this kind of assistance since long waiting lists make it difficult to provide such support. Several studies suggest that patients in the telemedicine group expressed high satisfaction with their care. They especially liked the convenience of a live video visit with a sleep doctor.

North America is expected to dominate the sleep apnea devices market during the forecast period

On the basis of region, North America accounted for the largest share of the global sleep apnea devices market in 2018, whereas, the Asia Pacific region registered the highest CAGR during the forecast period. North American accounted for the largest share owing to factors like an increase in the number of patients diagnosed with sleep apnea in the region, growth in awareness initiatives being taken by various government and non-government organizations, availability of adequate funding for research and development, and substantial growth in the usage of oral appliances in the region.

Major players operating in the sleep apnea devices market include ResMed (US), Koninklijke Philips (Netherlands), Fisher & Paykel Healthcare (New Zealand), SomnoMed (US), Oventus Medical (Australia), Compumedics (Australia), Löwenstein Medical (Germany), Drive DeVilbiss Healthcare (US), BMC Medical (China), Braebon Medical (Canada), and Panthera Dental (Canada).

Recent Developments:

# In 2019, ResMed (US) launched AirFit N30i, its first top-of-head-connected nasal CPAP mask, across the US with a newly designed nasal cradle cushion that sits just under the wearer’s nose.

# In 2016, Koninklijke Philips (Netherlands) launched its Dream Family solution which comprises of a DreamWear mask, DreamStation PAP device, and DreamMapper patient engagement app.

You Can Also Read More Detailed Article@
https://www.marketsandmarkets.com/Market-Reports/sleep-apnea-devices-market-719.html

Human Liver Models Market worth 2.56 Billion USD by 2022

The report “Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022", The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).

The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Objectives of the Study

# To define, measure, and describe the global human liver model market by type and region

# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW

Animal models accounted for the largest share of the market in 2017

The human liver models market is segmented on the basis of type into liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. In 2017, the animal models segment accounted for the largest share of the global market. The growth in the biosimilars market is expected to boost the preclinical market as the development of biosimilars and biopharmaceuticals requires an understanding of the mechanism of action, quantification of pharmacological effects, and interpretation of toxicological data.

Preclinical research also helps in securing a clear definition of targets. Moreover, as the patents for many blockbuster drugs are set to expire by 2020, the demand for biosimilars and preclinical services is likely to increase. The rising demand for preclinical services, in turn is expected to drive the demand for animal models.

Target Audience:

# Pharmaceutical and biotechnology companies

# Chemical companies

# Cosmetic product manufacturers, suppliers, and distributors

# Healthcare providers and diagnostic laboratories

# Manufacturers of 3D Cell Culture products

# Food & beverage manufacturers

# Contract research organizations (CROs)

# Research institutes/universities

# Research and consulting firms

# Venture capitalists

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

North America held the largest share of the market in 2017

In 2017, North America accounted for the largest share of the human liver models market, followed by Europe.

The market for human liver models in this region is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, favorable government initiatives, growing incidence of NAFLD, and unavailability of livers for transplantation, increased research spending, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.

The key players in the global human liver models market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).

Creatinine Assay Kits Market - Global Growth Boosting Factors | Technological Innovations

The report “Creatinine Assay Kits Market by Type (Jaffe’s Kinetic Test, Creatinine-PAP, and ELISA), Sample (Blood, Serum, Urine, Saliva, CSF, Tissue Homogenate, Sweat) and Region (North America, Europe, Asia and RoW) - Global Forecast to 2022", The global creatinine assay kits market is expected to reach USD 245.4 Million by 2022 from USD 189.6 Million in 2017, at a CAGR of 5.3%.

Increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders are the key drivers of the global creatinine assay kits market.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=73499229

The objectives of this study are as follows:

# To define, describe, and forecast the global creatinine assay kits on the basis of type, type of sample, and region

# To estimate the total number of Creatinine Measurement tests conducted by type and region

# To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)

# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for the market leaders

# To forecast the size of the market with respect to five regions: North America, Europe, Asia, and the Rest of the World (RoW)

# To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies

# To track and analyze competitive developments in the creatinine assay kits industry, such as acquisitions, agreements, product launches & upgrades, expansions, and R&D activities

In 2017, North America dominated the creatinine assay kits market

In 2017, North America dominated the market followed by Europe. The large share of North America is attributed to factors such as increasing incidence of renal disorders, rising prevalence of other chronic disorders like hypertension and diabetes (which can lead to renal dysfunction), and the implementation of favorable government initiatives to increase awareness of and encourage research pertaining to kidney diseases.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=73499229

The creatinine assay kits market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), Merck (Germany), Abbott Laboratories (US), Abcam (UK), Quidel (US), Enzo Life Sciences (US), Cayman Chemical (US), Crystal Chem (US), Cell Biolabs (US), Genway Biotech (US), BioAssay Systems (US), Wako Pure Chemical Industries (Japan), Tulip Diagnostics (India), BioVision (US), and Arbor Assays (US).

Agreements, acquisitions, and expansions accounted for the largest share of the overall growth strategies followed by key players between 2014 and 2017.

The creatinine assay kits market is highly fragmented in nature with many big and small players.

Thermo Fisher Scientific was the leading player in the creatinine assay kits market in 2016. The leading position of the company can be attributed to its strong brand recognition, customer loyalty, and extensive product portfolio. The company has a strong geographic presence and a keen focus on increasing its reach and enhancing its distribution network. Along with its wide distribution network, the company also adopts strategies like collaborations and agreements to retain its market position.

Merck KGaA ranked second in the creatinine assay kits market in 2016. The company has strong brand recognition and a wide geographical presence. The company prominently focuses on inorganic growth strategies such as agreements, collaborations, and acquisitions to strengthen its market position. It acquired Sigma-Aldrich (US), a multinational chemical, life science, and biotechnology company, for USD 17 billion. This acquisition made the company one of the leaders in the science and technology industry and helped it enhance its product portfolio, capabilities, and geographical presence

Read More Detailed Article@

https://www.marketsandmarkets.com/Market-Reports/creatinine-assay-kits-market-73499229.html

Stem Cell Banking Research to Grow Leaps-and-Bounds Due to Increasing and Advanced R&D Facilities

The global stem cell banking market is projected to reach USD 9,415.4 million by 2023 from USD 6,290.6 million in 2018, at a CAGR of 8.4% from 2018 to 2023.

Factors such as the growing awareness on the therapeutic potential of stem cells; development of novel technologies for stem cell preservation, processing and storage; increase in hematopoietic stem cell transplantation (HSCT) procedures; and increasing investments in stem cell-based research are driving the growth of the stem cell banking market.

However, the high operational costs associated with stem cell banking and stringent regulatory frameworks are expected to restrain market growth to a certain extent.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=220680183

Based on source, the placental segment is expected to witness the highest growth during the forecast period

On the basis of source, the stem cell banking market is categorized into six major categories, namely, placental, embryonic, bone marrow, adipose tissue, dental pulp, and other stem cell sources. In 2019, the placental segment is expected to be the fastest growing segment during forecast period. This can be attributed to the significant rise in the number of placental and cord banks across major markets (especially the US and Europe) coupled with growing public awareness about the therapeutic potential of stem cell sources.

Based on application, the personalized banking applications segment is expected to account for the largest share of the stem cell banking market in 2019

Based on application, the global stem cell banking market is segmented into clinical applications, research applications, and personalized banking applications. The personalized banking applications segment is expected to account for the largest share of the stem cell banking in 2019. The growth in this segment is primarily attributed to the premium pricing of service plans charged by service providers and specific advantages offered by personalized banking over community & public banking (such as exclusive member rights for stored stem cells as well as efficient quality analysis, sample testing, and sample processing).

Key questions addressed in the report:

# What are the growth opportunities related to stem cell banking market across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of stem cell banking. Will this scenario continue in the next five years?

# What are the various types of stem cell banking services and their market share in the overall market?

# What are the new trends and advancements in the applications segment?

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=220680183

By service, rising number of stem cell banks across emerging countries to drive the growth of market

On the basis of service, the stem cell banking market is segmented into sample collection and transportation, sample processing, sample analysis, and sample preservation & storage. The sample preservation & storage segment is expected to account for the largest share of the market in 2019. The large market share of this segment is primarily attributed to the increasing number of hematopoietic stem cell transplantations, increasing stem cell-based research, and high market penetration of stem cell banking services in major healthcare markets are driving the growth of this market segment.

North America is expected to dominate the stem cell banking market in 2019

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share in 2019. The expanding network of stem cell banking services across the region, ongoing approval of stem cell lines for disease treatment (especially for hematopoietic & autoimmune disorders), recent technological advancements in the field of stem cell collection and preservation techniques, and rising public-private investments for stem cell researches are driving the growth of the stem cell banking market in North America.

Recent Developments:

# In 2017, Life Cell International (India), launched upgraded and enhanced its umbilical cord collection kit

# In 2017, Vita34 AG (Germany) acquired Seracell Pharma AG (Germany) to strengthen its position in the German stem cell banking market.

# In 2016, StemCyte India Therapeutics Pvt. Ltd. (India), a subsidiary of StemCyte (US) received accreditation from The Foundation for the Accreditation of Cellular Therapy (FACT) for both public and private stem cell banking services.

# In 2015, Cord Blood Registry (CBR) Systems (US) entered into a collaboration agreement with New York Stem Cell Foundation (US) to develop induced pluripotent stem cells from umbilical cords

Feel FREE to Talk to Our Experts for More Detailed Information@

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=220680183

The major players in the market include Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico); among others.

Fertility Tests Market - Emerging Nations to Offer New Growth Avenues

This market is expected to reach USD 772.9 million by 2027 from USD 411.8 million in 2018, at a CAGR of 7.2%. The major factors driving the growth of the fertility test market include declining fertility rates across the globe, increasing first-time pregnancy age, introduction of advanced, user-friendly fertility monitors with high accuracy.

Recent Developments:

# In 2017, Swiss Precision Diagnostics (Switzerland) launched its Clearblue Connected Ovulation Test System

# In 2017, NFI Consumer Healthcare (US) a division of Gregory Pharmaceutical Holdings (US) completed the acquisition of e.p.t over-the-counter pregnancy test kit brand from Prestige Brands Holdings.

# In 2017, Fairhaven Health (US), launched TempCue, a basal body temperature (BBT) thermometer.

# In 2016, Fertility Focus (UK) launched OvuSense App.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139945432

The ovulation predictor kits segment accounted for the largest share of the market by product in 2018

The fertility test market is segmented on the basis of product into ovulation predictor kits, fertility monitors, and male fertility testing products. The fertility monitors segment is further categorized into urine-based, saliva-based and other fertility monitors. The ovulation predictor kits segment commanded the largest share of the global fertility test market in 2018. This is primarily due to their high efficacy and low cost, high preference for these products, ease of use, low cost as compared to fertility monitors, and easy OTC availability.

Non-Prescription/OTC –based is expected to account for a larger share of the market by mode of purchase in 2018

Based on the mode of purchase, the global fertility test market is classified into segments—prescription-based and non-prescription/OTC-based. The non-prescription/OTC-based segment is expected to account for a larger share of the fertility test market in 2018 due to its inclination of patients towards self-monitoring of healthcare conditions, increasing initiatives by market players to spread awareness on fertility, easy availability, and use of fertility and ovulation monitors on e-commerce websites.

Key Questions Addressed by the Report:

# What are the growth opportunities related to the adoption of fertility test products across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of ovulation prediction kits. Will this scenario continue in the next five years?

# Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?

# How will the increasing use of ovulation tracking mobile apps and fertility-tracking websites affect the growth of the market?

North America is expected to dominate the fertility test market during the forecast period.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the global fertility test market during the forecast period (2018-2023). The large share can be attributed to the growing use of fertility monitoring devices for contraception and rising awareness about the benefits of ovulation monitors through social media, marketing campaigns, and e-commerce sites. In addition, the emergence of advanced easy-to-use fertility monitors with high accuracy is one of the key factors propelling the growth of the fertility test market in North America.

You Can Also Talk to Our Experts for More Details@

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=139945432

The Major Players Operating in the Global Market Include:

# SPD Swiss Precision Diagnostics (Switzerland)

# Church & Dwight (US)

# Prestige Brands Holdings (US) and many more...

Analysis of the market developments between 2015 and 2018 revealed that several growth strategies such as product launches, enhancements, and strategic acquisitions were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the fertility test market. Among these business strategies, product launches was the most widely adopted growth strategies by the players in the fertility test market.

Laboratory Centrifuge - Advanced Systems to Boost R&D in Global Life Sciences Industry

The laboratory centrifuges market is expected to reach USD 1.2 billion by 2023 from USD 1.1 billion in 2018, at a CAGR of 2.8%. Market growth is primarily driven by factors such as technological advancements, increasing research, and a high prevalence of target diseases.

The hospitals segment to dominate the laboratory centrifuges market in 2018.

Based on end users, the laboratory centrifuges market is segmented into hospitals, biotechnology and pharmaceutical companies, and academic and research institutes. The hospitals segment is expected to account for the largest share of the laboratory centrifuges market in 2018. 

The increasing prevalence of diseases, coupled with the growing awareness regarding early diagnosis and treatment, increasing demand for blood, availability of novel and technologically advanced centrifuges for blood separation, and growing number of hospitals, especially in emerging countries, are some of the key factors driving the growth of the laboratory centrifuges market for hospitals.

Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197749088

Objectives Behind this Study:

# To define, describe, and forecast the laboratory centrifuge market on the basis of product type, rotor design, intended use, model type, application, end user, and region

# To analyze the market structure and provide a forecast of the market

# To analyze detailed information about factors influencing market growth (drivers, restraints, threats, and opportunities)

# To strategically analyze the micromarkets with respect to their individual growth trends, prospects, and contributions to the global market

# To analyze market opportunities for stakeholders and to draw a competitive landscape for key players

# To forecast the revenues of the market segments with respect to four main geographies, namely, North America, Europe, Asia, and the Rest of the World (RoW)

# To profile the key players and comprehensively analyze their market shares and core competencies

# To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, collaborations, and R&D activities in the laboratory centrifuge market

The benchtop centrifuges segment is expected to account for the largest market share of in 2018

On the basis of model type, the laboratory centrifuge equipment market is segmented into benchtop centrifuges and floor-standing centrifuges. Among these, the benchtop centrifuges segment is expected to account for the largest market share in 2018. Benchtop centrifuges are cost-effective, versatile, easy-to-use, smaller in size, and considerably lighter in weight. These advantages have resulted in their increased adoption in the laboratory centrifuges market.

Asia to grow at the highest CAGR during the forecast period

The laboratory centrifuges market has been segmented into four major regions, namely, North America, Europe, Asia, and the Rest of the World (RoW). Currently, North America dominates the global laboratory centrifuges market, and this trend is expected to continue during the forecast period.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=197749088

However, the market in Asia is estimated to grow at the highest CAGR during the forecast period. The presence of emerging economies such as China and India and the increasing R&D investments by pharmaceutical and biotechnology companies in this region are the major factors supporting the growth of the Asian laboratory centrifuges market.

Key players in the laboratory centrifuges market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Eppendorf AG (Germany), Sigma Laborzentrifugen GmbH (Germany), Andreas Hettich GmbH & Co. KG (Germany), Kubota Corporation (Japan), Koki Holdings Co., Ltd. (Japan) (previously Hitachi Koki Co., Ltd.), QIAGEN N.V. (Netherlands), NuAire (US), Sartorius (Germany), HERMLE Labortechnik GmbH (Germany), and Becton, Dickinson and Company (US).

Recent Developments:

# In 2016, Thermo Fisher Scientific launched Medifuge

# In 2016, Beckman Coulter partnered with Henry Ford Health System. This partnership aimed to enhance and streamline operations by fully automating the Henry Ford Hospital laboratory and modernizing the equipment at 12 other Henry Ford locations.

# In 2018, Eppendorf launched Centrifuge 5425

Key Questions addressed by the report:

# Where will all these developments take the industry in the mid to long term?

# Which are the key players in the market and how intense is the competition?

# Which are the recent contracts and agreements key players have signed?

Talk to Our Research Experts for More Detailed Info.@

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=197749088

Sterile Filtration - On-Going Tech Innovations | A Boon to Global Pharma & Biotech Industry

The study involved two major activities in estimating the current market size of the sterile filtration market. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

The sterile filtration market is projected to reach USD 7.4 billion by 2025 from USD 4.7 billion in 2019, at a CAGR of 8.0% during the forecast period. The major factors driving the growth of this market include the advantages of sterile filters over non-sterile filters, the growing demand for pure water in the end-user market, increasing adoption of single-use technologies, and rising focus on the development of large biopharmaceutical drugs.

Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=256410424

Report Objectives:

# To define, describe, and forecast the global market on the basis of product, membrane type, membrane pore size, application, end user, and region

# To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, opportunities, and industry-specific challenges)

# To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

# To forecast the size of the market with respect to five main regions (along with countries), namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa

# To strategically profile the key players in the global sterile filtration market and to comprehensively analyze their core competencies2 and market rankings

# To track and analyze competitive developments such as acquisitions, partnerships & collaborations, product launches, and expansions of the key players in the global market

Fill-finish process accounted for the largest share of the application segment in 2018

Based on application, the sterile filtration market is segmented into fill-finish processes, buffer filtration & cell culture media preparation, bioburden reduction, water purification, and air filtration. The fill-finish processes segment accounted for the largest market share in 2018. The fill-finish process is the final operation in the manufacturing of sterile products and demands the highest level of quality and reliability. This, in turn, drives the demand for sterile filters, as it is the most critical filtration step to ensure product sterility and safety.

Request Sample Pages@ 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=256410424

North America accounted for the largest share of the sterile filtration market in 2018

The large share of North America in this market is attributed to factors such as the strong presence of sterile filter product manufacturers in the region, the presence of a well-established biopharmaceutical industry, significant R&D spending by pharmaceutical and biotechnology companies, and the presence of a well-established intellectual property system for innovative biologics production.

The major companies in the global sterile filtration market are Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), 3M (US), and Parker Hannifin Corp (US).

Recent developments:

# In 2019, Merck (Germany) launched the Stericup Quick Release 500 ml Vacuum Filtration System

# In 2019, Merck (Germany)) expanded its distribution capacity in Gillingham, UK.

# In 2019, Sartorius (Germany) launched Sartolab MultiStation (filtration units).

# In 2018, Pall (US) established a Biotech Integrated Solutions Center of Excellence (CoE) in Shanghai, China. This center is equipped with advanced bioprocessing equipment, including single-use cell culture solutions, cell clarification using acoustic wave technology, chromatography using automated packing techniques, viral clearance, and tangential flow filtration, to serve bioprocess engineering consultancies for China and broader Asia.

Key questions addressed by the report:

# Who are the major market players in the sterile filtration market?

# What are the regional growth trends and the largest revenue-generating regions in the market?

# What are the major drivers and challenges in the market?

# What are the major product segments of the market?

# What are the major end users for sterile filtration?

Feel Free to Talk to Our Research Experts for More Detailed Article@ 

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=256410424

Active Pharmaceutical Ingredients Market - Emerging Industry Trends & Global Future Forecasts

The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

Report Objectives:

# To define, describe, and forecast the global APIs market on the basis of type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region

# To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)

# To strategically analyze micromarkets with respect to the individual growth trends, future prospects, and contributions to the overall market

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

# To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)

# To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies

# To track and analyze competitive developments such as partnerships, agreements, collaborations, joint ventures, alliances, mergers & acquisitions, approvals, expansions, and R&D activities in the global APIs market.

Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263

“The biotech APIs segment is expected to grow at the highest CAGR during the forecast period.”

On the basis of type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2019. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. The demand for biotech-derived molecules is growing significantly owing to their specificity in action. The demand for biologics is also increasing because they are similar to natural biological compounds found in the human body as compared to synthetic APIs, making this the fastest-growing segment in the market.

“The captive API manufacturers segment estimated to account for the largest share in 2019.”

Based on type of manufacturer, the APIs market can be divided into captive API manufacturers and merchant API manufacturers. In 2019, the captive API manufacturers segment is expected to account for the largest share of the APIs market. This can be attributed to the fact that most big pharmaceutical companies possess their API manufacturing facilities and are vertically integrated across the pharmaceutical supply chain. Moreover, innovator companies prefer in-house manufacturing of innovative products to avail economic benefit and prevent technology leakage.

Key Questions addressed by the report:

# Where will all these developments take the industry in the mid to long term?

# What types of annual and multi-year partnerships are API companies exploring?

# Which are the key players in the market and how intense is the competition?

# Which are the recent contracts and agreements key players have signed?

# What are the recent trends affecting the API manufacturers?

Request Sample Pages@ 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=263

“North America to dominate the market in 2019.”

In 2019, North America is expected to dominate the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures and the introduction of low-cost, generic versions of branded drugs.

The key players in the market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK).

Recent Developments

# In January 2018, Pfizer entered into a collaboration with Sangamo Therapeutics, Inc. (US) for the development of a potential gene therapy to treat amyotrophic lateral sclerosis (ALS).

# In May 2018, Novartis acquired AveXis, a clinical-stage gene therapy company, to develop a gene-based treatment for spinal muscular atrophy.

# In January 2018, Sanofi acquired Ablynx, a biopharmaceutical company to strengthen its platform for growth in rare blood disorders.

# In January 2018, Sanofi and Alnylam Pharmaceuticals, Inc. (US) announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize the development and commercialization of products prescribed for the treatment of rare genetic diseases.

Feel FREE to Talk to Our Research Experts for More Detailed Information@ 

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=263

Healthcare IT Market worth $390.7 billion by 2024

The healthcare IT market is projected to reach USD 390.7 billion by 2024 from USD 187.6 billion in 2019, at a CAGR of 15.8% during the forecast period. The demand for healthcare IT solutions and services is driven by government mandates & support for healthcare IT solutions, rising use of big data in healthcare, high returns on investment for healthcare IT solutions, and the need to curtail escalating healthcare costs.

Objectives of the Study

# To define, describe, and forecast the healthcare IT market based on product & service, component, end user, and region

# To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)

# To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market

# To analyze opportunities in the market for stakeholders and to provide details of the competitive landscape for market leaders

Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=252

# To forecast the size of the healthcare IT market with respect to five geographic regions – North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa

# To profile key players in the healthcare IT market and comprehensively analyze their core competencies2 and market shares

# To track and analyze competitive developments such as agreements, partnerships, and collaborations; mergers and acquisitions; new product/technology/service launches and upgrades; and research and development activities of leading players in the healthcare IT market

“The healthcare provider solutions segment is estimated to grow at the highest CAGR during the forecast period”

The healthcare provider solutions segment is estimated to witness the highest growth in the Healthcare IT market, by product and services, during the forecast period. Growth in this segment is attributed to the increasing demand for improved patient safety and patient care, stringent regulations regarding healthcare provider solutions, and the need for integrated healthcare systems.

“The healthcare payer fraud detection analytics market is estimated to witness high growth from 2019 to 2024”

Based on healthcare payers solutions, the market is segmented into claims management, customer relationship management, payer fraud analytics solutions, provider network management, pharmacy audit & analysis, member eligibility management, population health management solutions, and payment management solutions. The fraud analytics solutions is estimated to witness high growth from 2019 to 2024.

The growing incidence of healthcare fraud (leading to the increasing healthcare costs and rising insurance premiums) has compelled payers and other stakeholders in the market to increase their focus on adopting data analytics software for faster and efficient fraud detection and prevention.

Key Questions Addressed in the Report

# Who are the top 10 players operating in the healthcare IT market?

# What are the driving factors, restraints, opportunities, and challenges in the market?

# What are the industry trends as well as the current scenario in the healthcare IT market?

# What are the growth trends in the market at the segmental and overall market levels?

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=252

“North America dominated the Healthcare IT market in 2018”

The Healthcare IT market is broadly segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the Healthcare IT market in 2018. The large share of this region can be attributed to the technological competencies of healthcare industry and presence of well-established healthcare IT infrastructure in this regions. Changing regulatory requirements for improving quality of healthcare and increasing patient safety and rising healthcare expenditures are some of the key factors driving the growth of the healthcare IT market in North America.

Some of the major players operating in this market include Optum (US), Cerner (US), Cognizant (US), Change Healthcare (US), Philips Healthcare (Netherlands), Epic Systems (US), Dell Technologies (US), Allscripts (US), GE Healthcare (US), IBM (US), Athenahealth (US), Oracle Corporation (US), COnduent (US), Infor (US), Tata Consultancy Services (India), Wipro Limited (India), Conifer Health (US), Nuance (US), 3M (US), Inovalon (US), InterSystems (US), Leidos (US), Softheon (US), Omnicell (US), and Ciox Health (US).

Recent Developments:

# In 2019, Philips launched Cares Aging & Caregiving service.

# In 2018, Change Healthcare launched Dx Gap Advisor

# In 2017, Optum acquired DaVita Medical Group (US). The acquisition of DaVita enhanced Optum’s physician-led primary, specialty, in-home, and surgery-care delivery services business.

# In 2017, Cognizant acquired TMG Health (US) to expand its business process-as-a-service solutions for government and public health programs

# In 2018, Optum collaborated with Humana (US), MultiPlan (US) and Quest Diagnostics (US) to form a group to explore the blockchain technology to improve data quality and reduce administrative costs in healthcare

Feel FREE to Talk to Our Research Experts for More Detailed Information on This Topic@ 

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=252

Cardiovascular Ultrasound Systems - Reasons for Rising NEED for the Advanced Technologies

Target Audience:

# Cardiovascular ultrasound system manufacturers

# Cardiovascular ultrasound system distributors and wholesalers

# Pharmaceutical companies

# Various research and consulting firms

# Research institutes

# Contract manufacturing organizations (CMOs)

# Original equipment manufacturers (OEMs)

This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the cardiovascular ultrasound market along with the estimates and forecasts of the revenue. 

Key questions addressed by the report:

# Who are the major market players in the cardiovascular ultrasound system market?

# What are the regional growth trends and the largest revenue-generating regions for cardiovascular ultrasound system market?

# What are the major drivers and challenges in the cardiovascular ultrasound system market

# What are the major product segments in the cardiovascular ultrasound system market?

# What are the major end users for cardiovascular ultrasound system?

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=50389652

Increasing incidence of cardiovascular diseases, technological advancements, and advantages of echocardiography over invasive cardiac diagnostic procedures are the major drivers for the cardiovascular ultrasound system market. However, insufficient reimbursement scenario and economic impact of adopting new technologies are restraining the growth of the market.

Restraints:

# Unfavorable Reimbursement Scenario

# Economic Impact of Adopting New Technologies

Opportunities:

# Growth Potential in Untapped Emerging Markets

# Miniaturization of Ultrasound Devices

Challenges:

# Dearth of Skilled and Experienced Sonographers

On the basis of end user, the cardiovascular ultrasound system market is categorized into hospitals, cardiology centers, ambulatory, home care, and other end users (research institutes, medical device and pharmaceutical companies). The hospitals segment is expected to account for the largest share of the market in 2016. The home care & ambulatory segment is estimated to register the highest CAGR during the forecast period due to increase in the usage of echocardiographs at the patient’s house itself.

Key players in the cardiovascular ultrasound system market include GE Healthcare (U.S.), Philips healthcare (The Netherlands), Siemens Healthcare (Germany), Hitachi Medical Corporation (Japan), and Toshiba Medical Systems Corporation (Japan).

Key players in the market are majorly focusing on product launches and approvals to strengthen their position the market. In June 2016, FUJIFILM Medical Systems U.S.A. Inc., showcased the next generation of its Synapse Cardiovascular, a cardiac imaging tool and SonoSite iViZ, the latest portable ultrasound. Similarly, in November 2015, Siemens Healthcare (Germany) launched its new ultrasound imaging system, the HELX with Touch Control in its Healthcare Acuson S Family.

Request Sample Pages for more Details@ 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=50389652

Dermatology Devices Industry - Major Reasons Behind the Boost in the Global Revenue

This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the dermatology devices market, along with revenue estimates & forecasts and market share analysis.

The following are the major objectives of the study:

# To define, describe, and forecast the global dermatology devices market on the basis of type, application, and region

# To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific trends)

# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market

# To analyze the opportunities in the market for stakeholders and provide details of a competitive landscape for market leaders

Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=154

# To forecast the size (by value) of the market segments with respect to four main regions, namely, North America, Europe, Asia, and Rest of the World

# To strategically profile key players and comprehensively analyze their market shares and core competencies in terms of market development and growth strategies

# To track and analyze competitive developments such as partnerships, agreements, collaborations and joint ventures; mergers and acquisitions; new product launches; and research and development activities in the dermatology devices market

“The rising incidence of skin disorders, increasing awareness on aesthetic procedures, technological advancements, and increasing healthcare expenditure are the major factors driving the growth of this market.”

Restraints:

# Reimbursement Uncertainties and Issues

# Stringent Regulatory Policies

Opportunities:

# Emerging economies

Threat:

# Competitive Pricing by Low-cost Manufacturers, Availability of Low-cost Substitutes

Revenue Growth Predictions:

The global dermatology devices market is expected to reach USD 14.17 billion by 2021 from USD 8.22 billion in 2016, at a CAGR of 11.50%.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=154

Based on region, the global dermatology devices market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Growth in this regional segment is driven by factors such as the rising incidence of skin diseases, increasing healthcare expenditure, and increasing awareness regarding aesthetic procedures.

Some of the major players operating in the dermatology devices market are Alma Lasers, Ltd. (Israel), Cutera, Inc. (U.S.), Cynosure, Inc. (U.S.), Lumenis, Ltd. (Israel), and Valeant Pharmaceuticals International, Inc. (Canada).

Based on the analysis of strategic developments undertaken by market players between 2012 and 2016, the key strategies followed by most companies in the dermatology devices market are product launches and acquisitions.

Global Clinical Trial Management Systems Industry - Major Growth Boosting Factors

According to latest research report "Clinical Trial Management System Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) - Global Forecast to 2022", The global clinical trial management system (CTMS) market is expected to reach USD 1,065.6 million by 2022 from USD 590.0 million in 2017, at a CAGR of 12.6%. 

Factors such as significant outsourcing of clinical trial research to CROs, rising number of clinical trials, availability of advanced CTMS solutions, and rising government funds & grants to support clinical trials are driving the overall demand for CTMS across key markets.

Critical questions the report answers:

# What are the growth opportunities related to CTMS market across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of enterprise CTMS products. Will this scenario continue in the next five years?

# What are the various types of CTMS products and their market share in the overall market?

# What are the new trends and advancements in the clinical trials industry?

Please Share your Specific Interest So That We Can Serve You Better | Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=470

Recent Developments

# In November 2017, Bio-Optronics and Complion entered into a partnership in order to integrate and develop their solutions, namely, CTMS and eRegulatory Solutions

# In September 2017, Pamplona completed the acquisition of Paraxel and bought its shares in order to help PARAXEL increase its productivity.

# In May 2017, Oracle opened its Oracle Cloud EU Region in Germany, with the addition of modern infrastructure as a service (IaaS) architecture and new IaaS and platform as a service (PaaS) cloud services.

# In January 2017, MedNet Solutions released the latest version of iMedNet with enhanced features

# In June 2016, Bio-Optronics launched the latest version of the Clinical Conductor CTMS.

By end user, the contract research organizations segment is expected to grow at the highest rate during the forecast period

By end user, the CTMS market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, medical device companies, and others. The pharmaceutical and biopharmaceutical companies’ segment is sub-segmented into large pharmaceutical companies and mid-small pharmaceutical companies. The contract research organizations segment is expected to grow at the fastest rate during the forecast period in 2017. This is attributed to the rise in outsourcing of clinical trials by pharma and biotechnology companies to CROs.

Monetary Growth Expectations, Globally:

According to the Research Study conducted by MarketsandMarkets™: The global clinical trial management system (CTMS) market is expected to reach USD 1,065.6 million by 2022 from USD 590.0 million in 2017, at a CAGR of 12.6%.

Please Share your Specific Interest So That We Can Serve You Better | Request Sample Pages@ 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=470

Geographical Growth Scenario:

Geographically, the CTMS market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America is expected to account for the largest share of the global CTMS market during the forecast period (2017-2027). Factors such as rising number of on-going clinical trials (especially in the US), presence of leading players from both demand and supply sides, and government funding for clinical research are contributing to the large share of the North American region.

Leading Market Players:

# Oracle (US)

# Medidata Solutions (US)

# PAREXEL (US)

# Bioclinica (US)

# Bio-Optronics (US)

# IBM (US) and many more…

On-Going Growth in the Biologics Market is a Major Breakthrough for the Global Clinical Trial Supplies Industry

This study involved four major activities in estimating the current size of the clinical trial supplies market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. 

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Major Objectives of This Study:

# To define, describe, and forecast the market on the basis of service, phase, drug type, therapeutic area, and region.

# To provide detailed information regarding the major factors influencing the growth of the market

# To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the overall market.

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.

# To forecast the size of the market segments with respect to four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World.

# To profile key market players and comprehensively analyze their product portfolios, market positions, and core competencies.

# To track and analyze competitive developments such as acquisitions, new product launches, expansions, agreements, partnerships, collaborations, and R&D activities in the clinical trial supplies market.

Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=172240059

Recent Developments:

# In December 2019, Catalent launched the New CTSuccess Service to guide sponsors toward smarter clinical trial supply planning.

# In May 2019, Catalent completed the USD 1.2-billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies.

# In September 2019, Catalent announced that it would invest USD 9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020.

Factors Influencing Global Growth:-

The increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the globalization of clinical trials & harmonization of regulations are the key factors driving the growth of this market.

Restraints:

# Increasing Cost of Drug Development and Clinical Trials

Opportunities:

# Patent Expirations

# Emerging Markets

# Growth in the Biologics Market

Key Questions Addressed by the Report;

# Where will all these developments take the industry in the mid-to-long term?

# What are the recent trends affecting the market?

# Who are the key players in the market, and how intense is the competition?

# Which region is a lucrative market for clinical trial supplies?

Request Sample Pages@ 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=172240059

Monetary Growth Expectations, Globally:

According to the Research Study conducted by MarketsandMarkets™: The clinical trial supplies market is projected to reach USD 2.5 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 7.8%.

Geographical Growth Scenario:

The global clinical trial supplies market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. North America is the largest regional market for clinical trial supplies, followed by Europe. The large share of the North American market can primarily be attributed to the presence of well-established CROs and the high and growing R&D expenditure by pharmaceutical and biopharmaceutical companies in the region.

Leading Market Players:

# Alamc Group (UK)

# Catalent, Inc. (US)

# PCI Services (US)

# Parexel International Corporation (US)

# Sharp Packaging Services (US)

# Biocair (UK) and many more…

Catalent, Inc. (US) is the leading player in the global clinical trial supplies market. The company has an extensive network that provides comprehensive services to various pharmaceutical companies for phase I–IV clinical trials. Catalent’s offerings in the clinical trial supplies market include forecasting and planning services, packaging services, comparator sourcing, and distribution and logistics services. 

Almac Group (UK) is another major player in the global clinical trial supplies market. The company offers a wide range of services, from research through pharmaceutical and clinical development to the commercialization of products.

Read More Detailed Article@ 

https://www.marketsandmarkets.com/Market-Reports/clinical-trial-supplies-market-172240059.html

Key Players in the Gene Panel Market | Growth Strategies Adopted by Them

The global gene panels market is expected to reach USD 2.95 Billion by 2023 from USD 1.22 Billion in 2018, at a CAGR of 19.2%. Increasing prevalence of chronic diseases and growing company initiatives are some of the major factors responsible for driving this market.

The objectives of this study are as follows:

# To define, describe, and forecast the global gene panel market by product & service, technique, design, application, end user, and region

# To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for the key players

# To forecast the size of the market with respect to five regions: North America, Europe, Asia Pacific, and the Rest of the World

# To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies

# To track and analyze competitive developments in the gene panel market, such as agreements, collaborations, acquisitions, product launches, expansions, and R&D activities

Download PDF Brochure For More Details@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=101282859

Agreements, partnerships, joint ventures, and collaboration accounted for the largest share of the overall growth strategies followed by key players between 2015 and 2018. Some of the key players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), ), Novogene Corporation (China), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US).

Illumina led the global gene panel test kit market in 2017, it is a well-established company and one of the leading brand names in the market. The leading position of the company can be attributed to its exhaustive product portfolio and strong geographic presence. The company focuses on organic as well as inorganic growth strategies to enhance its market position, such as agreements, partnerships, and collaborations that allow it to access the capabilities of complementary businesses and expand geographically. In the last three years, Illumina collaborated with companies such as Thermo Fisher Scientific (2018), Pensabio (2015), and Amoy Diagnostics Co. Ltd. (2015).

Thermo Fisher Scientific is the second-largest player in the gene panel test kits market in 2017. The company adopts organic and inorganic growth strategies to enhance its market share. It is an innovation-centric company and invests heavily in R&D. For example, it spent 4.4% of its revenue in 2017 of R&D activities. This high R&D investment helps the company to introduce and upgrade its products in the market. Some products launched by the company recently are the Ion AmpliSeq On-Demand (2017) and Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel (2015). Product launches help the company to stay current in the market and provide innovative solutions to its end users.

Target Audience for this Report:

# NGS equipment manufacturers, vendors, and distributors

# NGS sequencing services companies

# NGS bioinformatics/data analysis companies

# Research institutes and government organizations

# Venture capitalists and government funding organizations

# Research and consulting firms

# Healthcare institutions

# Pharmaceutical and biotechnology companies

# Contract manufacturing organizations

# Contract research organizations

Read the Detailed Article@

https://www.marketsandmarkets.com/Market-Reports/gene-panel-market-101282859.html